Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Breast cancer is the most common cancer in the UK. Most women who get breast cancer are over 50 years of age and have already gone through the menopause.
There are many types of breast cancer. Triple negative is a form of breast cancer that does not respond to hormone treatments or other newer targeted treatments. Veliparib is a new treatment for women with early-stage triple negative breast cancer. Veliparib is given as a tablet taken twice daily. It is given in combination with the chemotherapy drugs carboplatin every 3 weeks and paclitaxel weekly, which are both given directly into the blood. Studies at the moment are aiming to show how well these treatments work together and that veliparib is safe to use.
If veliparib is licensed for use in the UK, it will provide a new treatment option for patients with early-stage breast cancer. Indexing Status Subject indexing assigned by CRD MeSH Benzimidazoles; Carboplatin; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000750 Date abstract record published 14/06/2016 |